Thanh Lan Quan, MD
Ophthalmology · Westminster, CANPI 1831133511
Payments from drug & device makers
Across 498 payments — averaging $30.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$2K
- AbbVie$2K
- Alcon$2K
- Bausch & Lomb Americas Inc.$1K
- Oyster Point Pharma, Inc.$1K
- Aerie Pharmaceuticals, Inc.$1K
- plus $6K from 20 others
What the payments were for
- Travel & lodging$10%
- Food & beverage$15,365100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 79 | $2,469 |
| AbbVie(2 entities) | 84 | $2,061 |
| Alcon | 51 | $1,636 |
| Bausch & Lomb Americas Inc. | 39 | $1,369 |
| Oyster Point Pharma, Inc. | 35 | $1,178 |
| Aerie Pharmaceuticals, Inc. | 47 | $1,130 |
| Lilly USA, LLC | 12 | $843 |
| Novartis | 51 | $739 |
| Amgen | 29 | $731 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $419 |
| Eyevance Pharmaceuticals LLC | 15 | $417 |
| Ivantis, Inc | 2 | $277 |
| LEO Pharma Inc. | 2 | $257 |
| Kala Pharmaceuticals, Inc. | 11 | $213 |
| Mallinckrodt Hospital Products Inc. | 4 | $194 |
| Tarsus Pharmaceuticals, Inc. | 9 | $190 |
| Beaver-visitec International, Inc. | 1 | $164 |
| Shire North American Group Inc | 4 | $149 |
| Glaukos Corporation | 2 | $138 |
| Galderma Laboratories, L.p. | 1 | $127 |
| AstraZeneca | 1 | $125 |
| Gilead | 1 | $123 |
| Dompe US, Inc. | 1 | $120 |
| Rxsight Inc | 1 | $111 |
| Harrow Eye, LLC | 5 | $107 |
| Dexcom, Inc. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$730
- VYZULTA$678
- XEN GLAUCOMA TREATMENT SYSTEM$525
- Rocklatan$485
- TALTZ$368
- Rhopressa$358
- CEQUA$355
- Hydrus Microstent$294
- Hydrus$277
- ADBRY$257
- XIIDRA$236
- ReSTOR$235
- LOTEMAX SM$231
- Voyager DSLT$145
- Tobradex ST$133
- NEMLUVIO$127
- Flarex$126
- iStent inject Trabecular Micro-Bypass Stent System$126
- Enbrel$125
- ANDEXXA$125
How this compares
$15,367 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 987 | $916,891 |
| XiidraLifitegrast | 653 | $575,650 |
| LumiganBimatoprost | 1,128 | $450,836 |
| Cyclosporine | 763 | $347,511 |
| CequaCyclosporine | 416 | $292,327 |
| VyzultaLatanoprostene Bunod | 519 | $195,825 |
| TyrvayaVarenicline Tartrate | 187 | $126,560 |
| MieboPerfluorohexyloctane/Pf | 158 | $125,760 |
| RhopressaNetarsudil Mesylate | 271 | $119,743 |
| CombiganBrimonidine Tartrate/Timolol | 185 | $63,475 |
| RocklatanNetarsudil Mesylat/Latanoprost | 113 | $60,711 |
| Alphagan PBrimonidine Tartrate | 161 | $51,879 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 122 | $33,692 |
| VevyeCyclosporine | 35 | $28,778 |
| ProlensaBromfenac Sodium | 65 | $22,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose | $2,061 | $1,493,0632,478 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $1,369 | $897,2351,330 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $2,469 | $292,327416 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,130 | $180,455384 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,178 | $126,560187 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Alrex, Lotemax Sm | $419 | $45,239162 claims |
| AlconSimbrinza, Azopt | $1,636 | $39,814139 claims |
| Harrow Eye, LLCVevye | $107 | $28,77835 claims |
| Eyevance Pharmaceuticals LLCZerviate | $417 | $6,30914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Westminster
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.